High response rate to αPD-1/PD-L1 therapy is often associated with immune inflamed cancer phenotype characterized by the presence in the TME of both CD4+ and CD8+ T cells, PD-L1 expression on infiltrating immune and tumor cells and many pro-inflammatory and effector cytokines, such as IFN-γ15. The gene discussed is CD8A; the disease is cancer.